SGLT2−/− mice with a db/db genetic background exhibited a dramatic improvement in hyperglycemia and plasma insulin levels as well as preserved pancreatic beta cell function, indicating the benefit of SGLT2 mutant mice as a means of demonstrating the efficacy of SGLT2 inhibition. The gene discussed is INS; the disease is Hyperglycemia.